🔗 Share this article

Given that the US undertakes historic adjustments to its vaccination recommendations, one figure has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning Covid vaccinations throughout the pandemic and has zeroed in on possible deaths after COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Schedule

Public health authorities had intended to unveil radical revisions to the pediatric immunization program in December, synchronizing the US with the Danish immunization schedule, according to reports – a significant shift that would place the US out of step with a large portion of the international standard with insufficient data for public health gain. The announcement has been postponed until the next year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for halting some pediatric shot schedules in the US to become more similar to the Danish model, a country with universal health coverage and a citizenry about the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccination policy – usually the domain of Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Background

Høeg has little discernible track record in pharmaceutical research, regulation or management, which has been customary for past leaders of the biologics center. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in leading a major agency. She has no expertise in industry regulation.”

Past directors of the center would “grasp laws and regulations and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that prior appointees who headed the center have had.”

This division has an enormous workload at the FDA, she stated.

“Many people just pays attention on the innovative therapies, but the off-patent medication office clears a multitude of generic medications. There is also a biosimilars program, over-the-counter program and so forth, and every single one have to be looked after,” Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant leadership component to the position, which manages in excess of 5,000 employees. “It’s a massive administrative position, if you perform it correctly,” the former official said.

Agency Reaction and Controversial Programs

Regarding inquiries about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among agency officials on vaccines, a representative stated that the “inquiries rely on flawed assumptions”.

“This background matches the duties of her position,” the spokesperson stated, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial priority voucher program, a contentious expedited therapy clearance system that reportedly worried her predecessors. “How are these drugs being selected for this fast-track system? Who takes the choices?” Dr. Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the FDA seems to be moving towards laxer rules of most medications, with the exception of shots.”

Public Track Record on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, past, critics observe. She released a analysis using unverified public submissions to determine the rate of heart inflammation after COVID-19 immunization. She advised the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the new administration included changing rules for novel immunizations and discontinuing “optional” vaccines, she said following the vote on a audio program. At the agency, Dr. Høeg has according to sources proposed barring teenage boys from getting COVID-19 vaccinations.

“She’s an all-around true believer who commences with her conclusions and reverse-engineers to fit the data in a very deceptive, fraudulent manner,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|